Kristen N Ganjoo

Clinical Focus

• Cancer> Lymphoma
• Cancer> Medical Oncology
• Oncology
• Soft Tissue Sarcoma
• Gastrointestinal Stromal Tumors

Administrative Appointments

• Assistant Professor of Medicine, Stanford University (2004 - present)
• Assistant Professor of Medicine, Indiana University (2000 - 2004)

Professional Education

Current Research Interests

Clinical research with new and novel therapies for lymphomas and sarcomas including anti-angiogenesis agents and hypoxia activating agents.

Clinical Trials

• CyberKnife Radiosurgical Treatment of Inoperable Early Stage Non-Small Cell Cancer Recruiting
• Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor Recruiting
• Observational Study of Diffuse Large B Cell Primary Breast Lymphomas Treated w/RCHOP +/- XRT Recruiting
• Paclitaxel + Bevacizumab (Avastin®) for the Treatment of Metastatic or Unresectable Angiosarcoma Recruiting
• Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma Recruiting

Publications

• A Phase 1 Study of AME-133v (LY2469298) an Fc-Engineered Humanized Monoclonal Antibody in FcγRIIIa-Genotyped Patients with Previously Treated Follicular Lymphoma. Forero-Torres A, de Vos S, Pohlman BL, Pashkevich M, Cronier DM, Dang NH, Carpenter SP, Allan BW, Nelson JG, Slapak CA, Smith MR, Link BK, Wooldridge JE, Ganjoo KN. Clin Cancer Res. 2012
• Maintenance Bevacizumab is Associated With Increased Hemoglobin in Patients With Advanced, Nonsquamous, Non-Small Cell Lung Cancer. Riess JW, Logan AC, Krupitskaya Y, Padda S, Clément-Duchêne C, Ganjoo K, Colevas AD, Pedro-Salcedo MS, Kuo CJ, Wakelee HA. Cancer Invest. 2012; 30 (3): 231-5
• A phase I study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma. Ganjoo KN, Cranmer LD, Butrynski JE, Rushing D, Adkins D, Okuno SH, Lorente G, Kroll S, Langmuir VK, Chawla SP. Oncology. 2011; 80 (1-2): 50-6
• Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial. Advani RH, Hong F, Horning SJ, Kahl BS, Manola J, Swinnen LJ, Habermann TM, Ganjoo K. Leuk Lymphoma. 2011
• Current and emerging pharmacological treatments for gastrointestinal stromal tumour. Ganjoo KN, Patel S. Drugs. 2011; 71 (3): 321-30